Skip to content

Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer

Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02777164
Enrollment
740
Registered
2016-05-19
Start date
2016-05-31
Completion date
2018-10-31
Last updated
2019-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The objective of the study is to estimate the diagnostic accuracy of cancer detection when MIRA technology is combined with mammography, by evaluating the area under the ROC curve (AUC) of mammography vs. mammography plus MIRA. This evaluation will be done in a Reader Study on a subset of women with histology confirmed cancer and healthy women with dense breast.

Interventions

MIRA Device imaging for adjunctive detection of breast cancer

Sponsors

Real Imaging Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

A. Subjects who are asymptomatic and scheduled to undergo routine screening mammography OR B. Subjects scheduled for image guided needle biopsy as a result of findings obtained during standard of care imaging modalities AND C. Subjects has a prior mammogram and have been diagnosed with extremely or heterogeneously dense breast tissue (Density C or D)

Exclusion criteria

1. Male by birth. 2. Individual is less than 30 and greater than 70 years old. 3. Contraindication to bilateral mammography or MRI 4. Subjects who are unable to read, understand and execute the informed consent procedure. 5. Subjects who have had mammography ultrasound or MRI examination performed on the day of the study prior to MIRA scan. 6. Subjects who have significant existing breast trauma. 7. Subjects who have undergone lumpectomy/mastectomy. 8. Subjects who have undergone breast reduction or breast augmentation. 9. Subjects who have undergone any other type of breast surgery, excluding surgical biopsy. 10. Subjects who have large breast scar / Breast deformation 11. Subjects who have undergone a breast needle biopsy or a surgical biopsy within the 6 month period prior to their intended enrollment into the study. 12. Subjects who have a temperature \> 100° F (37.8C) degrees on the day of the MIRA imaging 13. Subjects who are pregnant or lactating 14. Subjects with known Raynaud's Disease 15. Subjects that are claustrophobic or have physical limitations that do allow them to sit in the system chair for the required imaging session. 16. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices 17. Subject with kidney failure 18. Subject with known allergy to gadolinium 19. Subject with a history of multiple contrast MRI scans (more than 4 MRI scans over the past two year) 20. Inmates (45 CFR 46.306) or mentally disabled individuals 21. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy) 22. Subjects currently participating in another investigational clinical study 23. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase

Design outcomes

Primary

MeasureTime frame
The difference in the area under the ROC curve (AUC) of mammography plus MIRA compared to mammography alone.19 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026